The Neuro-oncology market is experiencing significant growth due to the increasing incidence of brain and spinal cord tumors, coupled with advancements in diagnostic technologies and treatment modalities. The market encompasses a range of therapeutic interventions, including surgery, radiation therapy, chemotherapy, and immunotherapy, aimed at treating primary and metastatic tumors of the central nervous system. Technological innovations, such as precision medicine approaches and targeted therapies, contribute to personalized treatment strategies. The rising demand for novel and effective treatments, coupled with ongoing research and development initiatives, drives market expansion. Geographically, North America and Europe dominate the market, given their advanced healthcare infrastructure. However, the Asia-Pacific region is emerging as a key market, driven by a growing awareness of neuro-oncological conditions and increasing healthcare investments. The market is characterized by collaborations, mergers, and acquisitions among key industry players to enhance treatment options and improve patient outcomes.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
